We are live on
!
Find out more
ABG
Ally Bridge Group Portfolio holdings
AUM
$124M
1-Year Est. Return
249.88%
This Fund
S&P 500
This Quarter
Est. Return
+25.8%
1 Year Est. Return
+249.88%
3 Year Est. Return
+942.29%
5 Year Est. Return
+671.08%
10 Year Est. Return
–
AUM
$168M
AUM Growth
+$82.6M
(+97%)
Cap. Flow
+$37.9M
Cap. Flow
% of AUM
22.57%
Top 10 Holdings %
Top 10 Hldgs %
72.94%
Holding
26
New
7
Increased
6
Reduced
7
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
argenx
ARGX
|
+$16.3M |
| 2 |
Olema Pharmaceuticals
OLMA
|
+$8.86M |
| 3 |
SLNO
Soleno Therapeutics
SLNO
|
+$8.82M |
| 4 |
CBAY
Cymabay Therapeutics
CBAY
|
+$8.73M |
| 5 |
ALPN
Alpine Immune Sciences Inc
ALPN
|
+$4.96M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cytokinetics
CYTK
|
+$6.58M |
| 2 |
Ardelyx
ARDX
|
+$3.6M |
| 3 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$3.06M |
| 4 |
MoonLake Immunotherapeutics
MLTX
|
+$2.04M |
| 5 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$1.94M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Jasper Therapeutics
JSPR
$29.4M
| $28.9M | 17.2% |
365,926
+51,510
| +16% | +$346K |
|
|
2
argenx
ARGX
$53.8B
| $13.3M | 7.93% |
+35,000
| New | +$16.3M |
|
|
SLNO
3
DELISTED
Soleno Therapeutics
SLNO
| $12.5M | 7.43% |
+309,950
| New | +$8.82M |
|
|
CBAY
4
DELISTED
Cymabay Therapeutics
CBAY
| $11.6M | 6.9% |
+489,938
| New | +$8.73M |
|
5
Xenon Pharmaceuticals
XENE
$6.6B
| $11.1M | 6.64% |
241,961
-25,000
| -9% | -$883K |
|
|
ITCI
6
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $10.1M | 6.03% |
141,348
-33,652
| -19% | -$1.94M |
|
|
7
Olema Pharmaceuticals
OLMA
$1B
| $9.25M | 5.51% |
+659,035
| New | +$8.86M |
|
|
APLS
8
DELISTED
Apellis Pharmaceuticals
APLS
| $8.98M | 5.35% |
150,000
-31,805
| -17% | -$1.61M |
|
|
9
MoonLake Immunotherapeutics
MLTX
$1.64B
| $8.66M | 5.16% |
143,479
-39,626
| -22% | -$2.04M |
|
10
Axsome Therapeutics
AXSM
$11.8B
| $8.03M | 4.78% |
100,862
-9,738
| -9% | -$651K |
|
|
MRUS
11
DELISTED
Merus
MRUS
| $7.56M | 4.5% |
274,923
+53,539
| +24% | +$1.25M |
|
|
ALPN
12
DELISTED
Alpine Immune Sciences Inc
ALPN
| $6.81M | 4.06% |
+357,271
| New | +$4.96M |
|
13
Geron
GERN
$924M
| $6.27M | 3.74% |
2,971,639
+750,000
| +34% | +$1.46M |
|
|
AMAM
14
DELISTED
Ambrx Biopharma Inc
AMAM
| $5.49M | 3.27% |
385,383
+104,294
| +37% | +$1.19M |
|
|
AVDL
15
DELISTED
Avadel Pharmaceuticals
AVDL
| $4.9M | 2.92% |
+347,036
| New | +$4.08M |
|
|
HARP
16
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $4.87M | 2.9% |
+428,400
| New | +$3.37M |
|
17
Amylyx Pharmaceuticals
AMLX
$1.97B
| $4.06M | 2.42% |
275,773
+3,083
| +1% | +$47.3K |
|
18
Praxis Precision Medicines
PRAX
$8.77B
| $1.57M | 0.93% |
70,424
-1
| -0% | -$18 |
|
19
Compass Therapeutics
CMPX
$369M
| $1.3M | 0.78% |
834,630
-80,000
| -9% | -$138K |
|
20
ProMIS Neurosciences
PMN
$136M
| $1.23M | 0.73% |
42,667
+21,390
| +101% | +$800K |
|
21
Context Therapeutics
CNTX
$55.1M
| $820K | 0.49% |
725,951
| – | – |
|
|
MDVL
22
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
| $529K | 0.32% |
117,897
| – | – |
|
|
23
Ardelyx
ARDX
$1.28B
| – | – |
-881,356
| Closed | -$3.6M |
|
24
Black Diamond Therapeutics
BDTX
$103M
| – | – |
-634,191
| Closed | -$1.82M |
|
|
25
Cytokinetics
CYTK
$10.9B
| – | – |
-223,382
| Closed | -$6.58M |
|
Similar funds
MP
EWP
WFA
VWM
EI
TC
IFO
CRW
Ally Bridge Group's Q4 2023 Portfolio in Review
As of Q4 2023, Ally Bridge Group held 26 positions worth $168M, up 97% from $85.2M the previous quarter. Its ten largest holdings account for 73% of the portfolio.
Ally Bridge Group deployed $37.9M of net new capital in Q4 2023, opening 7 new positions and adding to 6 existing holdings. Its largest new stake was argenx: 35,000 shares worth $13.3M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was MoonLake Immunotherapeutics, an estimated $2.04M trimmed.
- Ally Bridge Group's largest Q4 2023 buy was argenx: 35,000 shares worth $13.3M.
- Ally Bridge Group added most to Geron in Q4 2023, an estimated $1.46M increase.
- Ally Bridge Group's biggest Q4 2023 reduction was MoonLake Immunotherapeutics, cutting an estimated $2.04M.
- Ally Bridge Group fully exited Cytokinetics in Q4 2023, selling an estimated $6.58M.
- Ally Bridge Group's ten largest holdings make up 73% of its $168M portfolio in Q4 2023.
- Ally Bridge Group opened 7 new positions and closed 4 in Q4 2023.
- Ally Bridge Group's portfolio value rose 97% quarter-over-quarter to $168M.
Based on Ally Bridge Group's 13F filing for Q4 2023, filed 14 Feb 2024.